Literature DB >> 1704348

Isolation and characterization of protective cytolytic T cells in a rodent malaria model system.

P Romero1, J L Maryanski, A S Cordey, G Corradin, R S Nussenzweig, F Zavala.   

Abstract

Protective immunity against malaria is induced by immunization with irradiation-attenuated sporozoites. Here we report the isolation of cytolytic T-cell (CTL) clones from BALB/c (H-2d) mice immunized with either Plasmodium berghei or Plasmodium yoelii sporozoites. The epitopes recognized by these CTL can be mimicked by synthetic peptides corresponding to a homologous region in the CS proteins of both rodent malaria species. Both peptides are recognized by the CTL in the context of the same MHC class I molecule, H-2 Kd. In vivo adoptive transfer of the CTL clones into non-immune syngeneic mice protected them from a lethal challenge of infectious sporozoites.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1704348     DOI: 10.1016/0165-2478(90)90086-6

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  14 in total

1.  Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity.

Authors:  Naif Khalaf Alharbi; Alexandra J Spencer; Adrian V S Hill; Sarah C Gilbert
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240

2.  Naturally exposed populations differ in their T1 and T2 responses to the circumsporozoite protein of Plasmodium falciparum.

Authors:  W H H Reece; M Plebanski; P Akinwunmi; P Gothard; K L Flanagan; E A M Lee; M Cortina-Borja; A V S Hill; M Pinder
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

3.  Human cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein.

Authors:  A Malik; J E Egan; R A Houghten; J C Sadoff; S L Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

4.  Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria.

Authors:  S Li; M Rodrigues; D Rodriguez; J R Rodriguez; M Esteban; P Palese; R S Nussenzweig; F Zavala
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

5.  Role for CD8+ T cells in antichlamydial immunity defined by Chlamydia-specific T-lymphocyte clones.

Authors:  J U Igietseme; D M Magee; D M Williams; R G Rank
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

6.  Recombinant peptide replicates immunogenicity of synthetic linear peptide chimera for use as pre-erythrocytic stage malaria vaccine.

Authors:  Luciana M Silva-Flannery; Monica Cabrera-Mora; Jianlin Jiang; Alberto Moreno
Journal:  Microbes Infect       Date:  2008-10-26       Impact factor: 2.700

7.  Immunogenicity and protective efficacy of a recombinant yellow fever vaccine against the murine malarial parasite Plasmodium yoelii.

Authors:  Cristina T Stoyanov; Silvia B Boscardin; Stephanie Deroubaix; Giovanna Barba-Spaeth; David Franco; Ruth S Nussenzweig; Michel Nussenzweig; Charles M Rice
Journal:  Vaccine       Date:  2010-05-06       Impact factor: 3.641

8.  Expression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA.

Authors:  Toritse Orubu; Naif Khalaf Alharbi; Teresa Lambe; Sarah C Gilbert; Matthew G Cottingham
Journal:  PLoS One       Date:  2012-06-27       Impact factor: 3.240

9.  Cross-protection between attenuated Plasmodium berghei and P. yoelii sporozoites.

Authors:  M Sedegah; W W Weiss; S L Hoffman
Journal:  Parasite Immunol       Date:  2007-11       Impact factor: 2.280

10.  Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).

Authors:  Matthew G Cottingham; Rikke F Andersen; Alexandra J Spencer; Saroj Saurya; Julie Furze; Adrian V S Hill; Sarah C Gilbert
Journal:  PLoS One       Date:  2008-02-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.